Cargando…

Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene

Several studies indicate that the short arm of chromosome 17 is one of the most frequently altered regions in sporadic breast carcinomas (45–60%). In the present report the 17p13.3-ter locus in tumour DNA of breast cancer patients, along with their matching normal lymphocyte DNA, have been mapped wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liscia, D S, Morizio, R, Venesio, T, Palenzona, C, Donadio, M, Callahan, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362303/
https://www.ncbi.nlm.nih.gov/pubmed/10360661
http://dx.doi.org/10.1038/sj.bjc.6690427
_version_ 1782153424353099776
author Liscia, D S
Morizio, R
Venesio, T
Palenzona, C
Donadio, M
Callahan, R
author_facet Liscia, D S
Morizio, R
Venesio, T
Palenzona, C
Donadio, M
Callahan, R
author_sort Liscia, D S
collection PubMed
description Several studies indicate that the short arm of chromosome 17 is one of the most frequently altered regions in sporadic breast carcinomas (45–60%). In the present report the 17p13.3-ter locus in tumour DNA of breast cancer patients, along with their matching normal lymphocyte DNA, have been mapped with four markers (D17S5, D17S379, ABR and D17S34), spanning nearly 3 cM of the telomer. Sixty-five of 143 heterozygous tumours had lost at least one of the markers at the minimum region of loss (45%). High levels of loss of these distal markers on 17p13.3 are independent of TP53 mutations and are associated with tumour cell proliferation. A follow-up period of over 7 years demonstrates that loss of these markers correlates both with disease-free (P = 0.004) and overall survival (P = 0.007). In addition we show that for disease-free survival the prognostic power of this genetic alteration is second only to axillary lymph node involvement (3.1 vs 6.3 relative risk), and is a better predictor than the mutational status of TP53 (1.6 relative risk). Our results are further evidence of the presence, within the region, of at least a second tumour suppressor gene distal to TP53, that might be targeted by deletions. © 1999 Cancer Research Campaign
format Text
id pubmed-2362303
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23623032009-09-10 Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene Liscia, D S Morizio, R Venesio, T Palenzona, C Donadio, M Callahan, R Br J Cancer Regular Article Several studies indicate that the short arm of chromosome 17 is one of the most frequently altered regions in sporadic breast carcinomas (45–60%). In the present report the 17p13.3-ter locus in tumour DNA of breast cancer patients, along with their matching normal lymphocyte DNA, have been mapped with four markers (D17S5, D17S379, ABR and D17S34), spanning nearly 3 cM of the telomer. Sixty-five of 143 heterozygous tumours had lost at least one of the markers at the minimum region of loss (45%). High levels of loss of these distal markers on 17p13.3 are independent of TP53 mutations and are associated with tumour cell proliferation. A follow-up period of over 7 years demonstrates that loss of these markers correlates both with disease-free (P = 0.004) and overall survival (P = 0.007). In addition we show that for disease-free survival the prognostic power of this genetic alteration is second only to axillary lymph node involvement (3.1 vs 6.3 relative risk), and is a better predictor than the mutational status of TP53 (1.6 relative risk). Our results are further evidence of the presence, within the region, of at least a second tumour suppressor gene distal to TP53, that might be targeted by deletions. © 1999 Cancer Research Campaign Nature Publishing Group 1999-05 /pmc/articles/PMC2362303/ /pubmed/10360661 http://dx.doi.org/10.1038/sj.bjc.6690427 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Liscia, D S
Morizio, R
Venesio, T
Palenzona, C
Donadio, M
Callahan, R
Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene
title Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene
title_full Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene
title_fullStr Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene
title_full_unstemmed Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene
title_short Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene
title_sort prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362303/
https://www.ncbi.nlm.nih.gov/pubmed/10360661
http://dx.doi.org/10.1038/sj.bjc.6690427
work_keys_str_mv AT lisciads prognosticsignificanceoflossofheterozygosityatlocionchromosome17p133terinsporadicbreastcancerisevidenceforaputativetumoursuppressorgene
AT morizior prognosticsignificanceoflossofheterozygosityatlocionchromosome17p133terinsporadicbreastcancerisevidenceforaputativetumoursuppressorgene
AT venesiot prognosticsignificanceoflossofheterozygosityatlocionchromosome17p133terinsporadicbreastcancerisevidenceforaputativetumoursuppressorgene
AT palenzonac prognosticsignificanceoflossofheterozygosityatlocionchromosome17p133terinsporadicbreastcancerisevidenceforaputativetumoursuppressorgene
AT donadiom prognosticsignificanceoflossofheterozygosityatlocionchromosome17p133terinsporadicbreastcancerisevidenceforaputativetumoursuppressorgene
AT callahanr prognosticsignificanceoflossofheterozygosityatlocionchromosome17p133terinsporadicbreastcancerisevidenceforaputativetumoursuppressorgene